Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-29
2007-05-29
Nickol, Gary (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S252010, C530S300000, C530S308000
Reexamination Certificate
active
10679746
ABSTRACT:
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
REFERENCES:
patent: 4349352 (1982-09-01), Manning et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5631224 (1997-05-01), Efendic et al.
patent: 6329404 (2001-12-01), Ikeda et al.
patent: 2001/0047084 (2001-11-01), Knudsen et al.
patent: 0 733 644 (1996-09-01), None
patent: 0 861 666 (1998-09-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 96/20005 (1996-07-01), None
patent: WO 98/57636 (1998-12-01), None
patent: WO 99/03478 (1999-01-01), None
patent: WO 99/43708 (1999-09-01), None
patent: WO 00/00195 (2000-01-01), None
Bowen L, Stein PP, Stevenson R, Shulman GI: “The Effect of CP68,722, a Thiazolidinedione Derivative, on Insulin Sensitivity in Lean and Obese Zucker Rats.” Metabolism 40:1025-1030, 1991.
Chang Ay, Wyse BM, Gilchrist BJ, Peterson T, Diani AR: “Ciglitazone, a New Hypoglycemic Agent 1: Studies in OB/OB and DB/DB Mice, Diabetic Hamsters, and Normal and Streptozotocin-diabetic Rats.” Diabetes 32:830-38, 1983.
Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: “Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(Methylcyclohexylmethoxy)benzyl}-thiazolidine-2,4-dione (ADD-3878, U-63,287,Ciglitazone), a New Antidiabetic Agent.” Diabetes 32:804-810, 1983.
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: “Characterization of New Oral Antidiabetic Agent CS-045 Studies in KK and OB/OB Mice and Zucker Fatty Rats.” Diabetes 37: 1549-58, 1988.
Hvdberg A, Nielsen, T.M., Hilsted, J., Orskov, C., and Holst, J. J. “Effect of Glucagon-Like Peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man.” Metabolism, vol. 43, #1 Jan. 1994 pp. 104-108.
Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: “Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM.” Diabetes Care 14: 1083-86, 1991.
Kraigen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH: “A Potent in Vivo Effect of Ciglitazone on Muscle Insulin Resistance Induced by High Fat Feeding of Rats.” Metabolism 38: 1089-1093, 1989.
Kuzuya T, Iwamoto Y, Kosaka K, Yamanoushi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: “A Pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus.” Diabetes Res. And Clin Practice.
O'Rourke CM, Davis J, Saltiel AR, and Cornicelli JA: “Metabolic Effects of Troglitazone in the Goto-kakizaki rat, a Non-obese and Normolipidemic Rodent Model of Non-insulin-dependent Diabetes Mellitus.” Metabolism 46: 192-198, 1997.
Reasner, C. A., II: “Promising New Approaches,” Diabetes, Obesity Metab. (1999), 1 (Suppl. 1), pp. S41-S48 XP-000971954.
Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: “Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects.” Diabetes Care 15:193-203, 1992.
William GD, Delda A, Jordan WH, Gries C, Long GG, Dimarchi RD: “Subchronic Toxicity of the Thiazolidinedione, Tanabe-174 (LY 282449), in the Rat and Dog.” Diabetes 42: 1993.
Johnson William Terry
Stramm Lawrence Edward
Vignati Louis
Yakubu-Madus Fatima Emitsel
Chandra Gyan
Cox Gregory A.
Eli Lilly and Company
Nickol Gary
Stewart Mark J.
LandOfFree
Synergistic use of thiazolidinediones with glucagon-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic use of thiazolidinediones with glucagon-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic use of thiazolidinediones with glucagon-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3819480